UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009934
Receipt number R000011639
Scientific Title Effectiveness of Galantamine on the care burden of family caregivers of patients with Alzheimer's disease
Date of disclosure of the study information 2013/02/05
Last modified on 2015/09/28 19:51:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effectiveness of Galantamine on the care burden of family caregivers of patients with Alzheimer's disease

Acronym

Effectiveness of Galantamine on the care burden in Alzheimer's disease

Scientific Title

Effectiveness of Galantamine on the care burden of family caregivers of patients with Alzheimer's disease

Scientific Title:Acronym

Effectiveness of Galantamine on the care burden in Alzheimer's disease

Region

Japan


Condition

Condition

Alzheimer's disease

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine whether Galantamine relieves the care burden in Alzheimer's disease

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The Zarit Burden Interview

Key secondary outcomes

Neuropsychiatric Inventory


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Galantamine treatment

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

1. The subjects met the criteria of Alzheimer's disease in the Nationnal Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders association
(NINCDS-ADRDA)
2. The subjects score more than 15 and less than 27 in the MMSE.
3. outpatients

Key exclusion criteria

1. Alcoholics
2. patients with epilepsy
3.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yumiko Motoi

Organization

Juntendo University School of Medicine

Division name

Department of Neurology

Zip code


Address

Bunkyo-ku Hongo 2-1-1, Tokyo

TEL

03-3813-3111

Email

motoi@juntendo.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yumiko Motoi

Organization

Juntendo University School of Medicine

Division name

Department of Neurology

Zip code


Address

Bunkyo-ku Hongo 2-1-1, Tokyo

TEL

03-3813-3111

Homepage URL


Email

motoi@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University School of Medicine, Department of Neurology

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 02 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

Galantemine administration improved the score of apathy in NPI scale, however, it failed to improve the Zarit caregiver burden interview.

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 02 Month 02 Day

Date of IRB


Anticipated trial start date

2013 Year 02 Month 05 Day

Last follow-up date

2014 Year 11 Month 30 Day

Date of closure to data entry

2014 Year 11 Month 30 Day

Date trial data considered complete

2014 Year 11 Month 30 Day

Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 02 Month 02 Day

Last modified on

2015 Year 09 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011639


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name